Latest Atorvastatin Stories
A new study has found that Pfizer Inc.'s Lipitor and AstraZeneca's Crestor cholesterol drugs are both equally effective in treating coronary artery disease.
Among patients with sub-optimal low-density lipoprotein cholesterol (LDL-C) or high-density lipoprotein cholesterol (HDL-C) levels, use of the drug evacetrapib alone or in combination with statin medications was associated with significant increases in HDL-C levels and decreases in LDL-C levels.
Atorvastatin therapy was found to be ineffective in reducing atherosclerosis progression in children and adolescents with systemic lupus erythematosus (SLE).
Women with lupus are 50 times more likely to have a heart attack; and all lupus patients are eight times more likely to develop premature coronary heart disease than the general population.